Update date: 30 September 2026 | Source: U.S. FDA
At a Glance
- FDA’s notable drug approvals list dated 30 September 2026 includes Camzyos (mavacamten).
- FDA describes the approval as the first drug to improve functional capacity and symptoms in children with a rare inherited heart condition.
- Mavacamten is a cardiac myosin inhibitor and requires specialist prescribing and monitoring.
Clinical context
Mavacamten affects cardiac contractility through myosin inhibition. Because of its pharmacology and safety considerations, use requires careful patient selection, monitoring and adherence to the approved prescribing framework in the jurisdiction where it is used.
India status
An FDA approval does not automatically mean the same indication, age group or product is approved or commercially available in India. Indian clinicians should verify CDSCO-approved labeling and local availability before considering any regulatory extrapolation.
Official Source
FDA — Notable Drug Approvals, 30 September 2026
MedBodh note: This article is for regulatory and medical education only. Consult the current approved label and specialist guidance before clinical use.